Abstract
Purpose: We aimed to investigate the prognostic value of multiple immune cell markers including programmed death-ligand 1 (PD-L1) and poliovirus receptor (PVR) in head and neck squamous cell carcinoma (HNSCC) using archival tumor tissues Methods: Patients diagnosed with HNSCC who have undergone surgical resection in 2005–2012 were included. Correlations between PVR and PD-L1 expression and patient characteristics were analyzed by analysis of variance. The Kaplan–Meier method and log-rank test were used to estimate survival. P values < 0.05 were considered statistically significant. Results: In total, 375 primary tumor tissues were analyzed using immunohistochemistry. High PVR expression was associated with a poor prognosis in terms of overall survival (OS) and recurrence-free survival (RFS), and tumors with high PVR expression were associated with a short OS. PD-L1 tumor expression did not have a prognostic impact on survival. Univariate analysis revealed that OS and RFS were affected by age and p16 and PVR expression; multivariate analysis revealed that age and p16 and PVR expression were the most important determinants of RFS. Conclusion: PVR overexpression is a poor prognostic factor in patients with HNSCC and co-targeting PVR and PD-L1 may be a promising therapeutic option that needs further investigation.
Original language | English |
---|---|
Pages (from-to) | 2741-2750 |
Number of pages | 10 |
Journal | Journal of cancer research and clinical oncology |
Volume | 147 |
Issue number | 9 |
DOIs | |
Publication status | Published - 2021 Sep |
Bibliographical note
Funding Information:This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean Government (MSIT) (NRF-2017M3A9E9072669, 2017M3A9E8029717, NRF-2019M3A9B6065231(sc) to H.R.K. and 2018R1A2A1A05076997, 2017R1A5A1014560) and by a grant from the National R&D Program for Cancer Control, Ministry of Health and Welfare, Republic of Korea (HA16C0015, HA16C0015020019).
Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.
All Science Journal Classification (ASJC) codes
- Oncology
- Cancer Research